Australian biotech Medlab Clinical (ASX: MDC) has announced it has received notice from the European Patent Office of its intention to grant a patent covering the use of the company’s NanoCelle drug delivery platform.
The patent, filed in 2016 and titled Transmucosal and transdermal delivery systems, will provide protection for the NanoCelle sub-micron delivery system in European member states as well as the United Kingdom until 2036.
This is the second patent to be granted for NanoCelle following the receipt of an Australian patent last September.
Medlab has also filed patent applications in the United States, New Zealand, Singapore and Hong Kong.
Medlab chief executive officer Dr Sean Hall said this latest notice of intent from the European Patent Office represents another important validation of the company’s proprietary drug delivery platform and offers it protection in one of the world’s largest markets.
“The grant will not only bolster the competitive advantage of our pharmaceutical and nutraceutical portfolio; it will also support our robust research and development pipeline and commercial partnering focus,” he added.
Nanoparticle delivery system
Medlab’s NanoCelle technology creates nano-sized water-soluble particles that are designed to overcome particle delivery issues such as solubility and degradation.
An example of its use is in the delivery of medicine as a fine mist spray, where nanoparticle-sized molecules of the active pharmaceutical ingredient is delivered for absorption across the oral buccal mucosa, the pink fleshy interior of the cheek. It is then rapidly taken up into the bloodstream and patient is not ingesting it.
NanoCelle has potential applications both in and out of medicine, including small and large molecule pharmaceuticals, generic medicines, cosmetics, nutraceuticals, and textiles.
Medlab believes NanoCelle underpins its growth strategy by offering near-term partnering opportunities while enhancing the company’s pharmaceutical and nutraceutical portfolios.